Wealth Enhancement Advisory Services LLC purchased a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 17,759 shares of the medical research company’s stock, valued at approximately $3,337,000.
Several other institutional investors also recently made changes to their positions in the company. Beutel Goodman & Co Ltd. acquired a new stake in Amgen in the 2nd quarter valued at approximately $86,723,000. Natixis increased its position in Amgen by 2,612.1% in the 2nd quarter. Natixis now owns 529,816 shares of the medical research company’s stock valued at $97,799,000 after acquiring an additional 510,281 shares during the period. Dimensional Fund Advisors LP increased its position in Amgen by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after acquiring an additional 343,690 shares during the period. Bank of Nova Scotia increased its position in Amgen by 234.2% in the 2nd quarter. Bank of Nova Scotia now owns 433,450 shares of the medical research company’s stock valued at $80,011,000 after acquiring an additional 303,743 shares during the period. Finally, Royal London Asset Management Ltd. acquired a new stake in Amgen in the 2nd quarter valued at approximately $54,522,000. Institutional investors and hedge funds own 82.37% of the company’s stock.
Several analysts recently commented on AMGN shares. Cann restated a “buy” rating and issued a $224.00 target price on shares of Amgen in a research report on Monday, October 1st. Royal Bank of Canada restated a “neutral” rating and issued a $193.00 target price on shares of Amgen in a research report on Monday, September 10th. Oppenheimer restated a “buy” rating and issued a $224.00 target price on shares of Amgen in a research report on Tuesday, August 28th. Goldman Sachs Group restated a “buy” rating and issued a $229.00 target price on shares of Amgen in a research report on Friday, October 12th. Finally, Jefferies Financial Group set a $220.00 target price on Amgen and gave the company a “buy” rating in a research report on Monday, October 8th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $204.55.
Shares of AMGN stock opened at $193.16 on Friday. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $210.19. The firm has a market cap of $125.93 billion, a PE ratio of 15.35, a PEG ratio of 2.05 and a beta of 1.37. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The company had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. During the same period last year, the firm earned $3.27 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, research analysts expect that Amgen, Inc. will post 14.24 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.73%. The ex-dividend date is Thursday, November 15th. Amgen’s dividend payout ratio is presently 41.97%.
ILLEGAL ACTIVITY NOTICE: “Wealth Enhancement Advisory Services LLC Takes $3.34 Million Position in Amgen, Inc. (AMGN)” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/11/10/wealth-enhancement-advisory-services-llc-takes-3-34-million-position-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.